Navigation Links
Tengion Advances Clinical Trial for Neo-Urinary Conduit™ in Bladder Cancer Patients
Date:11/16/2010

EAST NORRITON, Pa., Nov. 16, 2010 /PRNewswire-FirstCall/ -- Tengion, Inc. (Nasdaq: TNGN), a leader in regenerative medicine, announced today that the scheduled one-month, post-operative clinical assessment of the first implanted bladder cancer patient in its ongoing clinical trial has been completed as expected and has permitted the second patient to be enrolled without delay.  The protocol for this initial clinical trial calls for each of the first few patient implantations to occur at least eight weeks after the previous patient surgery.  The surgical procedure may be modified in subsequent patients based on the experience gained by the prior patient(s) enrolled.  No modifications to the protocol have been made based on the experience with the first patient.

"We are very encouraged by the response we have seen so far in our first patient and we look forward to continuing to advance this trial and to enrolling additional patients," commented Sunita Sheth, M.D., Vice President and Chief Medical Officer at Tengion.

This trial is evaluating Tengion's Neo-Urinary Conduit in bladder cancer patients requiring a urinary diversion following bladder removal (cystectomy).  The ongoing study is designed to provide data on the safety profile for the Neo-Urinary Conduit as well as to optimize the surgical technique and the ideal post-surgical patient care before proceeding into larger trials.  The first two patients are being treated at the University of Chicago Medical Center by the principal investigator at the site for this study, Gary D. Steinberg, M.D., Professor of Surgery and Director, Urologic Oncology. The trial is also being conducted at a second clinical site at The Johns Hopkins Hospital in Baltimore, Maryland.

Tengion expects to implant five patients by the middle of 2011 with scheduled three-month clinical assessments on all patients e
'/>"/>

SOURCE Tengion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
2. Tengion Launches Third Phase 2 Clinical Trial of Regenerated Human Bladder
3. Preclinical Data Demonstrate Ability to Regenerate an Entire Bladder With Tengion Neo-Bladder Replacement(TM)
4. Tengion Scientists Publish Key Preclinical Findings Demonstrating the Benefits of Organ Regeneration Vs. Repair
5. Tengion Appoints Sunita B. Sheth, M.D., Chief Medical Officer
6. Tengion Presents New Data Demonstrating Functional Regeneration in a Diabetic Chronic Kidney Failure Model at the International Society for Cellular Therapy
7. Tengion Announces First Implantation of Neo-Urinary Conduit™ in Initial Clinical Trial in Patients with Bladder Cancer
8. Tengion Reviews Pipeline Progress at First Analyst and Investor Meeting; Strategic & Clinical Updates Provided for Regenerative Medicine Programs
9. Tengion Provides Business Update and Reports Third Quarter 2010 Financial Results
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... 26, 2014  When it comes to diabetes supplies, innovations ... But Timesulin happens to answer a real medical need. ... on the market, Timesulin shows how long it,s been ... from missed or double insulin doses. Very easy to ... on the insulin pen after an injection. There is ...
(Date:8/26/2014)... ANDOVER, Mass. , Aug. 26, 2014 Acelleron ... and Eatontown, N.J ., is expanding.  Acelleron, ... Fitness to form a new division, Acelleron Maternal Health & ... their clients by providing a full range of resources for ... has been named the director of maternal wellness. Vecchi, ...
(Date:8/26/2014)... , Aug. 26, 2014 SynCardia Systems, Inc., ... high on the Inc. 5000 named by the business ... world,s only FDA, Health Canada and CE approved Total ... a matching donor heart transplant," says Michael P. ... the standard of care for patients dying from end-stage ...
Breaking Medicine Technology:Montméd obtains reimbursement of Timesulin, the smart insulin pen timer cap, by major insurance companies in Canada 2Suzanne Vecchi Named Director of Newly Acquired Acelleron Maternal Health & Wellness 2Inc. Magazine Ranks SynCardia Systems in Top 3rd in its 2014 Inc. 5000 List 2
... Oct. 13 Cellectis bioresearch, a specialist in ... today announced that it has established a US ... Innovation Center in Cambridge, Massachusetts, Cellectis bioresearch Inc. ... Cellectis bioresearch products and services. Cellectis ...
... Watson Pharmaceuticals, Inc. (NYSE: WPI ), a ... to release its third quarter 2010 financial results on Thursday, ... financial markets.  The Company will also host a conference call ... 4, 2010 to discuss its financial results and provide an ...
Cached Medicine Technology:Cellectis bioresearch Announces Establishment of Subsidiary in the US 2Cellectis bioresearch Announces Establishment of Subsidiary in the US 3Watson to Host Conference Call and Webcast to Discuss Third Quarter 2010 Earnings 2
(Date:8/27/2014)... Overcoming a turbulent past which branded KC Armstrong ... Women’s Radio Network, WRNW1, has recently signed a multi-million dollar ... to the WRNW1 family. KC states, “it is such a ... atmosphere.” After KC Armstrong publicly announced his appreciation to Howard ... show, “Howard 100 News,” have decided to pay it forward. ...
(Date:8/27/2014)... IntelliSoft Group, LLC, a leading provider of ... IntelliCred, IntelliApp and IntelliContract Version 14.2 ... (NHAMSS) Annual Conference on September 16, 2014 at the ... Notable improvements available in IntelliSoft’s Version 14.2 ... Linking: A new Contract Connection Tab connects the healthcare ...
(Date:8/27/2014)... Time to Play Golf, a fast-growing golf ... , With 80-degree temperatures and only partially clouded skies, the ... Inaugural Outing. Around 50 golfers showed up to duel it ... Heron Glen Golf Course in Ringoes, New Jersey. , The ... be having a great time. Birdies were dropping and those ...
(Date:8/27/2014)... Los Angeles, California (PRWEB) August 27, 2014 ... unveiled its “Journey Candle Collection” to provide a growing number ... executives a scent-based tool for goal setting and relaxing at ... of six soy candles, uses scent memory and visualization to ... milestone in their life each time they light a candle ...
(Date:8/27/2014)... 2014 Michael A. Bottar ... of The Best Lawyers In America© for the practice ... Injury Litigation - Plaintiffs." , Bottar received his undergraduate ... laude graduate of Syracuse University College of Law where ... Practice" chapter of the Syracuse Law Review Survey of ...
Breaking Medicine News(10 mins):Health News:The Women's Radio Network, WRNW1, Signs KC Armstrong to a Multi-Million Dollar Contract 2Health News:IntelliSoft Group to Unveil Version 14.2 of IntelliCred, IntelliApp and IntelliContract at the New Hampshire Association of Medical Staff Services Annual Conference 2Health News:Recap: Time To Play Golf Inaugural Golf Outing 2Health News:In My Solitude Unveils Eco Candle Line That May Improve Performance 2Health News:Michael A. Bottar Selected For Inclusion In The Best Lawyers In America© 2015 2
... 25 WellPoint, Inc. (NYSE:,WLP) announced today that ... Healthcare Conference on January 30, 2008. The presentation ... Time., All interested parties are invited to ... http://www.wellpoint.com and selecting the "Investor,Info" link. ...
... 25, 2008 Researchers from Mayo Clinic in ... stents (SEPSs) in the treatment of benign esophageal disease ... stent migration and few cases of long-term improvement. They ... patient populations and to guide future recommendations for the ...
... must pass more than lip service reform in wake ... The following is a,statement by Executive Director, Kurt Entsminger, ... are among the most restrictive,in the nation. To get ... by the symptoms of an illness like,schizophrenia to be ...
... Bill Novelli,made the following statement about next Monday,s vote on ... by the California State Senate,Committee on Health:, "On behalf ... the members of the State Senate Health Committee to pass ... Monday. ABX 1 1 represents a major step toward,ensuring that ...
... Inc. ("Assurant"),(NYSE: AIZ ), a premier provider of ... its board of,directors has declared a quarterly dividend of ... March 10, 2008 to shareholders of record as of,Feb. ... at the discretion of the,board of directors and will ...
... 25, 2008 --New York, NY-- Researchers in Belgium have ... with the capacity to generate new insulin-producing beta cells. ... the newfound progenitor cells may represent an obvious target ... researchers report in the Jan. 25 issue of the ...
Cached Medicine News:Health News:WellPoint Announces Appearance at Upcoming Conference 2Health News:Study examines self-expanding plastic stents in the treatment of benign esophageal conditions 2Health News:Study examines self-expanding plastic stents in the treatment of benign esophageal conditions 3Health News:Virginia Must Prize Mental Illness Treatment Over Psychosis 2Health News:Virginia Must Prize Mental Illness Treatment Over Psychosis 3Health News:Elusive pancreatic progenitor cells found in mice 2
... The Bio-Optics LSM-12000 is a new ... powerful new tool in anterior segment diagnostics ... easy to operate, easy to maintain, and ... is the only High Magnification Slit-Lamp Biomicroscope ...
70 discs to investigate acquired color deficiency. Quantifies neutral zone characteristics of dyschromatopsia and evaluates the relative luminance....
... a rapid field or laboratory test for the ... simple, two-step test provides results in 10 minutes, ... , ,Intended use: The NOW® Hepatitis B sAg/eAg ... the detection of Hepatitis B surface antigen (HBsAg) ...
... the newest technology available in acrylic lens ... exceptional material and design properties to achieve ... , Unique foldable hydrophobic acrylic material ... biostable , High index of refraction ...
Medicine Products: